Background:  This is a  Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes POST Worsening Heart Failure Trial Registration No: NCT03521934 ( Link  Sponsor:  Sanofi  Trial Status: recruiting  Enrolling Centers:  Worldwide: 384 centers Core Study Team Basel:
© Christian Mueller, 2012 - 2019 │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: October 2019
Home News Team Studies Publications Events Cooperations Contact Kristin Shrestha Beate Hartmann Ph.D. Eleni Michou
Dr. Dayana Flores Dr. Matthias Diebold Rafal Czmok